Does anti-thymocyte globulin have a place in busulfan/ fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and chronic GVHD and other clinical outcomes in matched related-donor HSCT. Methods: Sixty-one patients received allogeneic HSCT from human leukocyte antigen-matched, related donors. Patients received busulfan/fludarabine conditioning regimens and standard GVHD prophylaxis with or without additional ATG. Results: There was no significant difference in the cumulative incidences of overall acute GVHD, grade II to IV acute GVHD at day 100, and chronic GVHD during the follow-up period between the ATG and non-ATG groups. Three-year overall survival rates were very similar, but three year disease-free survival of the non-ATG group was higher than that of the ATG group (56.2% for ATG vs. 63.1% for non-ATG, p = 0.597). Relapse rate at 3 years in the ATG group was slightly higher than that of the non-ATG group (37.5% vs. 20%, p = 0.29). Non-relapse mortality rate at 3 years was lower in the ATG group (6.25% vs. 15.6%, p = 0.668). Conclusions: Although the addition of ATG doesn’t guarantee a reduction in the incidences of acute and chronic GVHD, pre-transplantation ATG may result in lower non-relapse mortality in the context of matched related-donor HSCT with a busulfan/fludarabine conditioning regimen. However, caution is needed when using ATG because of a possibility to increase relapse rate.
Abstract
Background/Aims: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and chronic GVHD and other clinical outcomes in matched related-donor HSCT. Methods: Sixty-one patients received allogeneic HSCT from human leukocyte antigen-matched, related donors. Patients received busulfan/fludarabine conditioning regimens and standard GVHD prophylaxis with or without additional ATG. Results: There was no significant difference in the cumulative incidences of overall acute GVHD, grade II to IV acute GVHD at day 100, and chronic GVHD during the follow-up period between the ATG and non-ATG groups. Three-year overall survival rates were very similar, but three year disease-free survival of the non-ATG group was higher than that of the ATG group (56.2% for ATG vs. 63.1% for non-ATG, p = 0.597). Relapse rate at 3 years in the ATG group was slightly higher than that of the non-ATG group (37.5% vs. 20%, p = 0.29). Non-relapse mortality rate at 3 years was lower in the ATG group (6.25% vs. 15.6%, p = 0.668). Conclusions: Although the addition of ATG doesn’t guarantee a reduction in the incidences of acute and chronic GVHD, pre-transplantation ATG may result in lower non-relapse mortality in the context of matched related-donor HSCT with a busulfan/fludarabine conditioning regimen. However, caution is needed when using ATG because of a possibility to increase relapse rate.
참고문헌 (25)
- Cutler C, "Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis", J Clin Oncol, 19, pp.3685~3691 (2001)
- Flowers ME, "Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial", Blood, 100, pp.415~419 (2002)
- Finke J, "Standard graftversus-host disease prophylaxis with or without anti-Tcell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial", Lancet Oncol, 10, pp.855~864 (2009)
- Duggan P, "Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis", Bone Marrow Transplant, 30, pp.681~686 (2002)
- Basara N, "Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group", Bone Marrow Transplant, 35, pp.1011~1018 (2005)
- Finke J, "Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin", J Clin Oncol, 21, pp.506~513 (2003)
- Zander AR, "ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)", Bone Marrow Transplant, 32, pp.355~361 (2003)
- Lu DP, "Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched", haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation, 2006, pp.107, 3065~3073
- Champlin RE, "Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens", Blood, 109, pp.4582~4585 (2007)
- Russell JA, "Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versushost disease: a matched pair analysis", Biol Blood Marrow Transplant, 13, pp.299~306 (2007)
- Baron F, "Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor:a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation", Bone Marrow Transplant, 49, pp.389~396 (2014)
- Fehse N, "Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation", J Hematother Stem Cell Res, 12, pp.237~242 (2003)
- Bosch M, "Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation", Cytotherapy, 14, pp.1258~1275 (2012)
- Keun Wook Bae, "Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children", Blood Research, 47(1), pp.44~52 (2012), 대한혈액학회
- Bacigalupo A, "Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)", Blood, 98, pp.2942~2947 (2001)
- Liu H, "Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study", J Hematol Oncol, 6, pp.15~ (2013)
- Ji Hyun Lee, "Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia", myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide, 2010, pp.45(2), 102~108[DOI]
- Andersson BS, "Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML", MDS, 2008, pp.14, 672~684
- Chae YS, "New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2", Bone Marrow Transplant, 40, pp.541~547 (2007)
- Shimoni A, "Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning:the role of dose intensity", Leukemia, 20, pp.322~328 (2006)
- Przepiorka D, "1994 Consensus Conference on acute GVHD grading", Bone Marrow Transplant, 15, pp.825~828 (1995)
- Devillier R, "A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor", Am J Hematol, 89, pp.83~87 (2014)
- Devillier R, "Higher doses of antithymocyte globulin (ATG) increase the risk of relapse in acute myeloid leukemia (AML) patients undergoing matched related donor allogeneic transplantation in first complete remission (CR1): an analysis from the acute leukemia working party of EBMT", Blood, 124, pp.729~ (2014)
- Lee SJ, "Severity of chronic graftversus-host disease: association with treatment-related mortality and relapse", Blood, 100, pp.406~414 (2002)
- Nash RA, "Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versushost disease after marrow transplantation from unrelated donors", Blood, 96, pp.2062~2068 (2000)